More importantly, we showed that early stage ovarian cancer patients with high mRNA levels of at least one of the two genes, GPC6 and TMEM132D, exhibited increased overall survival compared to patients with low levels of both genes. This evidence concerns the gene GPC6 and ovarian carcinoma.